ZoomRx polled 50 experienced oncologists and hemato-oncologists about 20 cancer drugmakers, asking the doctors to rank the ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, ...

Visit the American Cancer Society’s Cancer Statistics Center for more key statistics. Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors ...

Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused ...

Metastatic colorectal cancer (mCRC) continues to pose a clinical and commercial challenge, with low 5-year survival rates and limited durable respons ...

Q1 2025 Earnings Call Transcript May 12, 2025 Quanterix Corporation beats earnings expectations. Reported EPS is $-0.42, ...

“I think 20 years is the right balance between giving as much as we can to make progress on these things and giving people a lot of notice that now this money will be gone,” Gates sai ...

Amid the trends, pharma-targeted ETFs are being watched ... Policy Sensitivity: But its large weighting in companies with substantial Medicaid and U.S. sales exposure renders it highly sensitive ...

“Our Ex-US business delivered strong growth of 43 per cent across all markets, whereas the US business grew 20 per cent during the quarter,” he added. Alembic has been focusing on markets like the EU, ...

Investors seeking the next breakthrough in precision oncology may want to take note of Nuvectis Pharma (NASDAQ ... all development-stage biotechnology companies, significant risks remain.

Celebrating its 10th year, World ADC is returning to London bigger and better than ever. Covering the A to Z of ADCs, World ADC London will continue to curate and distil the field’s latest ...

The Q1 earnings season has provided a window into what the pharmaceutical industry expects from US President Donald Trump’s tariffs this year. Credit: Shutterstock ...